August 2021

The kinase inhibitor is a promising treatment option for patients with MET exon 14 skipping mutation non–small cell lung cancer.

Technicians play a key role in this vital element of pharmacy operations, protecting drug efficacy and against errors.

Between 40% and 50% of patients respond long term without relapsing.

Directions in Oncology Pharmacy is getting to know oncology pharmacy professionals through a series of interviews. In this issue, we talk to Ashley E. Glode, PharmD, BCOP, who was recently named an Advocacy Champion by the American Society of Clinical Oncology (ASCO).

The pharmacist can provide information and support that patients with cancer need to get through what might be the most challenging time of their lives.

The agents that have been evaluated and approved, and those that are coming in the pipeline, make for an exciting time to consider directed therapies.

As health care costs rise and cost-sharing increases, treatment-associated expenses will continue to burden patients.

A proactive approach can ensure that the patient is getting the right therapy at the right time and the right treatment plan with the least amount of waste.

The FDA has approved Qelbree (viloxazine extended-release capsules; Supernus Pharmaceuticals, Inc) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in pediatric patients aged 6 to 17 years.

Atrial fibrillation, bleeding, infection, and other adverse events may occur with this therapy.

The pandemic taught the pharmacy to provide a deeper level of personalized care and communication than in the past.

New treatments show promise for patients with KRAS G12C–mutated disease.

New potential medications may continue to expand the role of targeted agents.

Current guideline recommendations include various combinations of targeted therapy with immunotherapy.

A number of prescription medications are indicated for the treatment of this aggressive disease.

This month, I thought it would be beneficial to share a handful of examples from among the many Next Generation Pharmacist-nominated candidates.

As treatments for lung cancer move forward and patient care services continue to expand, the role of the pharmacist in oncology is critical.